Every Form 4 that LYRA THERAPEUTICS INC (LYRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LYRA filings page.
Lyra Therapeutics director W. Bradford Smith reported a disposition of common stock back to the company. On this Form 4, he returned 640 shares to the issuer in a transaction coded as a disposition to issuer at a reported price of $0.00 per share, leaving him with no directly held shares afterward.
Lyra Therapeutics director and Principal Executive Officer Maria Palasis reported returning 2,000 shares of Common Stock to the company in a disposition to the issuer at $0.00 per share. After this transaction, she directly owns 1,094,733 shares, indicating only a small portion of her holdings was affected.
Lyra Therapeutics Principal Financial Officer Jason Cavalier returned 667 shares of Common Stock to the company. The disposition to the issuer carried a reported price of $0.00 per share. After this transaction, he directly owns 517,880 shares, indicating this was a small, routine adjustment to his holdings.
Lyra Therapeutics, Inc. Chief Financial Officer Jason Cavalier reported a small, pre-arranged sale of 769 shares of common stock. The sale occurred on 01/06/2026 at a price of $3.364 per share under transaction code "S." According to the filing, the shares were sold to cover taxes triggered by the vesting of restricted stock units under a mandatory Rule 10b5-1 trading instruction adopted on January 1, 2025.
Following this tax-withholding sale, Cavalier beneficially owns 518,547 shares of Lyra Therapeutics common stock in direct form. The transaction is characterized as administrative in nature, tied to equity award vesting rather than an open-market discretionary sale.
Lyra Therapeutics, Inc. reported an insider tax-related share sale by its President & CEO, Maria Palasis. On 01/06/2026, she sold 1,702 shares of Lyra common stock at a price of $3.364 per share. The filing states that these shares were sold to cover taxes due upon the vesting of restricted stock units, under a mandatory Rule 10b5-1 trading instruction adopted on January 1, 2025. After this transaction, she beneficially owned 1,096,733 shares of Lyra common stock directly.
Lyra Therapeutics (LYRA): insider transactions reported. Perceptive-affiliated entities disclosed multiple open-market sales of common stock on 11/11/2025, 11/12/2025, and 11/13/2025. Reported weighted average prices were $4.3146, $4.0594, and $3.9001, respectively.
Following these transactions, the filing shows Perceptive Life Sciences Master Fund, Ltd. with 124,859 shares and Perceptive LS (A), LLC with 14,026 shares, each held indirectly. The filing notes that prices reflect weighted averages over multiple trades and that the reporting persons disclaim beneficial ownership beyond their indirect pecuniary interests.
Lyra Therapeutics (LYRA): Director-affiliated entities reported sales of common stock. A Form 4 shows multiple sales on 11/06/2025, 11/07/2025, and 11/10/2025 at weighted average prices of $5.1799, $4.7467, and $4.5398, respectively. The transactions were reported as indirect holdings tied to Perceptive Life Sciences Master Fund, Ltd. and Perceptive LS (A), LLC.
Following these transactions, beneficially owned shares reported were 166,101 for the Master Fund and 18,659 for Perceptive LS. Footnotes note prices are weighted averages with individual trade prices available upon request. Reporting persons include Perceptive Advisors, LLC, Perceptive LS GP, LLC, and Joseph Edelman, who is listed as a director and reports indirect ownership as described.
Lyra Therapeutics insider amendment corrects previously reported stock-option activity and clarifies current holdings. The reporting person, Maria Palasis, was originally granted performance stock options totaling 11,000 shares (stated as 550,000 pre-split) on 03/21/2024, but those PSOs were forfeited for no value on 02/14/2025. An earlier Form 4 filed on 10/03/2025 mistakenly reported the acquisition of 3,667 PSOs; this amended Form 4/A, filed on 10/08/2025, reverses that entry and states the Reporting Person currently does not beneficially own any of the PSOs granted on 03/21/2024. The filing was signed by an attorney-in-fact and notes the transaction price of the related employee stock option as $303.5 with an expiration of 03/20/2034.
Maria Palasis, President & CEO and a director of Lyra Therapeutics, Inc. (LYRA), reported a change in beneficial ownership after the company determined on 10/01/2025 that Milestone 2 under a performance stock option (PSO) award was achieved. The PSO grant, originally made on 03/21/2024, covered up to 11,000 shares; 3,667 PSOs were earned as a result of Milestone 2. Those earned PSOs are exercisable under the award terms and will vest on 01/31/2028. Following the reported transaction, the filing shows 7,333 shares of common stock beneficially owned directly by the reporting person. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Palasis and dated 10/03/2025.